Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentric randomized phase III study comparing high doses of chemotherapy with rituximab followed by auto-transplant HPC versus CHOP plus rituximab as first line therapy in high risk patients with DLBCL non-Hodgkin's lymphomas

Trial Profile

Multicentric randomized phase III study comparing high doses of chemotherapy with rituximab followed by auto-transplant HPC versus CHOP plus rituximab as first line therapy in high risk patients with DLBCL non-Hodgkin's lymphomas

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Melphalan; Mitoxantrone; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 10 Dec 2012 Primary endpoint 'Event-free-survival-rate' has not been met.
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top